Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
|Articles|October 1, 2002
Allergan, FDA communicate on Botox ads
Irvine, Calif. - Allergan Inc., contrary to popular belief, isn't fighting the U.S. Food and Drug Administration's allegations that statements in Botox Cosmetic advertisements are misleading, thus violating of the Food, Drug, and Cosmetic Act.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitor Safety in Atopic Dermatitis: Long-Term Epidemiology Data
2
Roflumilast Eases Sexual Difficulties in Psoriasis With Genital Involvement
3
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
4
Managing Treatment Expectations in Hidradenitis Suppurativa: What to Tell Patients Before Starting Therapy
5